Davanat FDA Approval Status

FDA Approved: No
Brand name: Davanat
Company: Galectin Therapeutics Inc.
Treatment for: Targeted Drug Delivery

Davanat is a polysaccharide polymer comprised of mannnose and galactose in development for the targeted delivery of drugs used in the treatment of cancer.

Development timeline for Davanat

Date	Article
Sep 15, 2008	Pro-Pharmaceuticals Submits Data to FDA for Davanat NDA to Treat Advanced Colorectal Cancer
May 20, 2008	Pro-Pharmaceuticals Announces Submission of Drug Master File forDavanat to FDA
May 1, 2008	Pro-Pharmaceuticals Updates NDA Filing for Davanat
Dec 19, 2007	Pro-Pharmaceuticals Selects SAFC, a Division of Sigma-Aldrich, toSubmit a Drug Master File
Jun 11, 2007	Pro-Pharmaceuticals Submits Data to Begin a 505 (b)(2) Filing withthe FDA for a New Formulation of Irinotecan to be Co-administeredwith Davanat as a Functional Excipient
Apr 11, 2007	Pro-Pharmaceuticals Receives Letter from the FDA for New DrugApplication for Davanat/ 5-FU
Feb 7, 2007	Pro-Pharmaceuticals' Begins Process of New Drug Application Submission with the FDA for Co-administration of Davanat with 5-FU in Cancer Patients

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer